Paper · 23940216
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Batchelor TT and 20 others. J Clin Oncol, 2013. Cited by 467 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Papers, record 23940216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23940216
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
- PubMed
- Publication types
- Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Brain Neoplasms | Major topic |
| Glioblastoma | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Female | |
| Follow-Up Studies | |
| Humans | |
| International Agencies | |
| Lomustine | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Quinazolines | |
| Survival Rate | |
| Indoles |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| K24 CA125440 | NCI NIH HHS | United States | K24CA125440 | PubMed and NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00777153 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04516733 | Precoce Medical Care by the Mobil Support for Patients With Glioblastoma | Results | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 24,934,784 | Reply to M.C. Chamberlain. | https://conductscience.org/library/papers/24934784 | PubMed |
| Comment in | 24,934,790 | Is there a role for vascular endothelial growth factor receptor 2 inhibitors in glioblastoma? | https://conductscience.org/library/papers/24934790 | PubMed |
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10,561,324 | Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561324 | PubMed |
| 2 | 19,720,927 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19720927 | PubMed |
| 3 | 19,897,538 | FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. | Oncologist | 2009 | https://conductscience.org/library/papers/19897538 | PubMed |
| 4 | 20,124,186 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20124186 | PubMed |
| 5 | 19,917,841 | Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/19917841 | PubMed |
| 6 | 16,407,877 | Lessons from phase III clinical trials on anti-VEGF therapy for cancer. | Nat Clin Pract Oncol | 2006 | https://conductscience.org/library/papers/16407877 | PubMed |
| 7 | 9,988,225 | Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. | Int J Cancer | 1999 | https://conductscience.org/library/papers/9988225 | PubMed |
| 8 | 1,028,239 | Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride. | Trans Am Neurol Assoc | 1976 | https://conductscience.org/library/papers/1028239 | PubMed |
| 9 | 19,114,704 | Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19114704 | PubMed |
| 10 | 15,899,831 | AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/15899831 | PubMed |
1 to 10 of 23
See all 23 referencesCited by338
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 467 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,958,602 | Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42958602 | PubMed |
| 42,941,343 | The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/42941343 | PubMed |
| 42,824,982 | Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42824982 | PubMed |
| 42,724,852 | A single-center retrospective study evaluating the efficacy of anlotinib plus temozolomide for recurrent glioma based on real-world data. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724852 | PubMed |
| 42,694,176 | Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis. | Front Neurol | 2026 | https://conductscience.org/library/papers/42694176 | PubMed |
| 42,589,248 | Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589248 | PubMed |
| 42,548,479 | Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control. | Front Oncol | 2026 | https://conductscience.org/library/papers/42548479 | PubMed |
| 42,493,681 | Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42493681 | PubMed |
| 42,251,229 | Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42251229 | PubMed |
| 42,088,219 | Efficacy and safety of tyrosine kinase inhibitor combination therapy for glioblastoma: a meta-analysis with trial sequential analysis of randomized controlled trials. | Front Oncol | 2026 | https://conductscience.org/library/papers/42088219 | PubMed |
1 to 10 of 338
See all 338 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CEDIRANIB | CHEMBL491473 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL491473 | ChEMBL |
| LOMUSTINE | CHEMBL514 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL514 | ChEMBL |
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23940216
GET https://conductscience.org/api/papers/v1/23940216/authors?page=2